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6(36) after parent drug administration. Surprisingly, and in contrast to data published by Carlin et al., 1992, M1 was not present in quantifiable concentrations in any of the examined body fluids (Lundahl et al., 2009 ). If it is assumed that at least 70% of the given finasteride dose was absorbed into the enterocytes and 22% of the dose was quantified after 24 hours sampling of urine and 3 hours sampling of bile, it follows that almost 50% of the dose remains to be identified. The St. John's wort treatment significantly reduced the area under plasma concentration-time curve (AUC) for finasteride, but the AUC for M3 remained unchanged. This indicated that both the formation and elimination of M3 were induced by the St John's wort treatment or the presence of other inducible parallel metabolic pathways.
The major objective of this study was to further investigate the metabolism of finasteride and to identify previously unknown phase I and phase II metabolites excreted to human bile and urine. The unique possibility of sampling using Loc-I-Gut enabled us to directly search for metabolites in human bile.
8 (36) methanol (750 µL). Each sample was centrifuged (10,000 g, 10 minutes) and the supernatant was separated and frozen at -20°C pending analysis.
Microsomal Incubations with UDPGA. M1 and M3 (final concentrations 100 µM)
were incubated with human liver microsomes and UDPGA for 24 hours. The incubations were carried out according to the method described by Fisher et al., 2000 . First, the microsomes (2 mg) were activated with alamethicin (25 µg) in potassium phosphate buffer (0.1 M, pH 7.1). After 15 minutes on ice, the substrate was added together with saccharolactone (5 mM, final concentration) and magnesium chloride (1 mM, final concentration) and pre-incubated for 6 minutes at 37°C. To start the reaction, UDPGA (5 mM, final concentration) was added and the final volume of the reaction mixture was 200 µL. MilliQ-water was added to the 0 hour-samples instead of UDPGA. The methanol content in the incubation mixture did not exceed 0.5%. The incubation was carried out at 37°C and the reaction was stopped with ice cold acetonitrile (150 µL). After 30 minutes on ice, the samples were centrifuged (10,000 g, 10 minutes) and the supernatant separated and frozen at -20°C pending analysis. In addition, finasteride (final concentration 200 µM) was incubated with human liver microsomes (8 mg/ml) according to the same protocol with two co-factors, NADPH (1 mM) and UDPGA (5 mM).
Incubations with UGT Supersomes. M1 and M3 were incubated with all 12 commercially available UGT supersomes. The incubations were carried out identically for all the different supersomes (37°C for 24 hours). Each incubation mixture, total volume 200 µL, contained the substance (200 µM), supersomes (1 mg/ml), potassium DMD 27870 9(36) phosphate buffer (0.1 M, pH 7.4), magnesium chloride (5 mM) and UDPGA (5mM).
Water was added instead of UDPGA for the 0 hour sample. The methanol content in the incubation mixture did not exceed 1%. The reaction was stopped by adding 150 µL ice cold acetonitrile to the sample. After 30 minutes on ice the samples were centrifuged (10,000 g, 10 minutes) and the supernatant separated and frozen at -20°C pending analysis.
Incubations with PAPS and GSH. For sulphate conjugation, incubations with 100 µM of M1, M3 and finasteride in human liver S9 fractions (2.5 mg/ml) in the presence of PAPS (4 mM) were performed according to the method described by van der Woude et al., 2004 . For glutathione conjugation of the metabolites or possible reactive intermediates, incubations with 100 µM of M1, M3 and finasteride with human liver microsomes (2 mg/ml) in the presence of GSH (5 mM) and NADPH (1 mM) were performed according to the method described by Kang et al., 2007 . A 0.1 M potassium phosphate buffer (pH 7.4) was used for both the GSH and PAPS incubations. The enzymatic reactions were terminated with acetonitrile (1:1) followed by centrifugation (10,000 g, 10 minutes) and separation of the supernatant, which was then frozen at -20°C pending analysis.
Subjects and Study Design. Details and results of the investigation of the clinical pharmacokinetics of finasteride and the interaction of St. John's wort with finasteride are reported elsewhere (Lundahl et al., 2009 Drug Administration and Bile Sampling. Finasteride (5 mg) was administered directly to the proximal jejunum as a suspension via the intestinal perfusion tube, Loc-I-Gut (Bergman et al., 2006 , Knutson et al., 1989 , Lennernas et al., 1992 . On arrival at the clinic in the morning after an overnight fast of 10-14 hours, the Loc-I-Gut tube was introduced orally and positioned in the distal duodenum/proximal jejunum below the papilla of Vater. The position of the tube was verified by fluoroscopy. The tube comprised two inflatable balloons and in this study the proximal balloon was inflated with 20-25 ml of air. Finasteride was administered into the jejunum together with the non-absorbable marker, [ 14 C]-polyethylene glycol 4000, distally to the inflated balloon DMD 27870
11 (36) and bile was quantitatively collected proximal to the balloon. A vacuum pump was connected to the tube to facilitate the bile collection. Bile was collected in 20 minutes intervals for a total of 3 hours after finasteride administration. Blank bile samples were collected before finasteride was administered. The samples were kept on ice during collection and then weighed, fractionated and frozen at -20 °C pending analysis. In this study, bile from 7 individuals was analyzed for the presence of phase I and phase II metabolites.
Urine Sampling. Urine was quantitatively collected into BD Vacutainer® Collection
Containers, 3 L, at intervals of 0-3, 3-6, 6-9, 9-12 and 12-24 hours after finasteride administration. One blank sample was collected before finasteride was administered.
Each sample was weighed, fractionated and frozen at -20 °C pending analysis. In this study, urine from 6 individuals was analyzed for the presence of phase I and phase II metabolites.
Sample Preparation and Hydrolysis. For hydrolysis of urine or bile samples, 100
Sigma units of β-glucuronidase in 100 µL acetate buffer (0.5 M, pH 4.9) were added to 100 µL of urine/bile and the samples were placed in a 37°C water bath for 1, 2 or 24 hours. The reaction was stopped with 100 µL of acetonitrile and a centrifugation (12,000 g, 6 minutes) was carried out prior to analysis. The supernatant was used for the LC-MS/MS analysis. The hydrolysis was performed according to the method described by Shibasaki et al., 2001 . Non-hydrolysed urine samples were directly analysed without any sample preparation. Bile was diluted (1:2) with MilliQ water and centrifuged (12,000 g, 6 This article has not been copyedited and formatted. The final version may differ from this version. Table 1 for proposed structures and Fig. 2a for a spectrum.
Hydrogen/deuterium (H/D) exchange using deuterium oxide (D 2 O) in the mobile phase, was used to elucidate the number of exchangeable protons of the studied ions, in order to facilitate structural determination. Finasteride standard gave product ions at m/z 320 (317+3) and 307 (305+2) upon H/D exchange, indicating that m/z 317, as shown in Table   1 , contained three labile protons, i.e. the two bound to the two nitrogens and the one carrying the charge. The shift for m/z 305 was also in accordance with the suggested structure, as it was protonated and contained only one nitrogen.
Full product ion scan of M1 standard with the precursor ion m/z 389 corresponding to [M+H] + , resulted in the main fragments at m/z 372, 318/317, 300, 272
and 72, see proposed structures in Table 1 and a spectrum in Fig. 2b . The ion at m/z 372 (-17 u from 389) could be formed by the loss of an OH radical or NH 3 . The option that this fragment was formed by the loss of ammonia from the A ring was considered Table 1 for proposed structures of the fragments and Fig. 2c for product ion spectrum.
This article has not been copyedited and formatted. The final version may differ from this version. Table 1 ). Furthermore, it was concluded from MS 3 measurements that m/z 272 was the same fragment for both M1 and MX (results not shown). In summary, the mass spectral data mentioned above indicated that MX was hydroxylated on a carbon, and not on the steroid skeleton. However, all the methyl groups on the tertiary butyl group are identical, which means that no side chain hydroxylation different from that of M1 could be formed. Another plausible step might be that MX is a ring-closed form of M1, where the hydroxyl group has attacked the amide carbon, forming a five-membered ring lactol-type structure. As the mass spectral data suggest that MY is hydroxylated on the steroid skeleton, it is likely that this metabolite is identical to the previously described M4. However, no reference compound was available for complete confirmation.
Phase I Metabolites Detected
In Vivo in Human Bile and Urine. M3 has previously been quantified in plasma, bile and urine (Lundahl et al., 2009 ). M1, which has been described as a main metabolite in humans (Carlin et al., 1992) , was not detected in any of the body fluids in this or the previous study and was not identified after β-glucuronidase (Fig. 3) . The intensities of the peaks increased after β-glucuronidase hydrolysis, suggesting that these compounds were mainly excreted as glucuronic acid conjugates to both bile and urine. Identification of an intact conjugate will be presented below.
In addition, bile and urine samples were analyzed for the presence of the aldehyde, M2, and dihydroxy-metabolites. There was no clear evidence for the presence of either of those forms, neither with nor without hydrolysis.
Phase II Metabolites Produced In Vitro.
The results from this study show that glucuronidation was the most important conjugation pathway for the finasteride phase I metabolites. One glucuronide with the precursor ion m/z 565 (389 +176 u) was produced when finasteride was incubated with NADPH and UDPGA for 24 hours in alamethicintreated human liver microsomes (Fig. 5a ). After full product ion scan of m/z 565 (CID, 35V) the glucuronide (7.5 minutes peak) gave the fragments m/z 389, 371, 333, 315, 298, 272 and 270. The spectrum corresponded to that of MY and it was concluded that the identified conjugate was MY glucuronide.
M1 and M3 were both glucuronidated after incubation of alamethicin-treated human liver microsomes in the presence of UDPGA. Two typical chromatographic patterns for M1 glucuronide (Fig. 6a ) and M3 glucuronide (Fig. 6b) were found, using 
Discussion
In this study, novel metabolites of finasteride were identified, in vivo, in human bile and urine. Two hydroxy-metabolites, MX and MY, were identified. MX is described for the first time in this paper and it is possible that it is a ring-closed form of M1. It was considered likely that MY was identical to the previously found M4. Furthermore, MY glucuronide, was identified in this study. It was the first time that intact glucuronides of finasteride were identified. MY glucuronide was the major glucuronide in human bile and urine. M1 was glucuronidated in vitro but the glucuronide was not identified in the in vivo samples. M3 was also glucuronidated in vitro and trace amounts of the glucuronide was identified in human bile.
Previously, the phase I metabolism of finasteride has been investigated and four major metabolites identified, M1-M4 (Fig.1) , of which two are hydroxy-metabolites (M1 and M4) (Ishii et al., 1994 , Huskey et al., 1995 . Another hydroxy-metabolite (11-α-hydroxy finasteride) was produced in vitro, after incubation with green algae (Selenastrum capricornutum), but was not identified in humans (Venkataramani et al., 1994) . M4 was described as a minor metabolite in human plasma (Carlin et al., 1987) .
M1 was previously identified as a major metabolite in human and dog plasma and the fraction of formed M1 was lower in humans than in dogs. The M1 concentrations were determined by high performance liquid chromatography with ultraviolet detection (HPLC-UV) after oral administration of high doses of finasteride (10 or 80 mg/kg to dogs and 38 mg to humans) (Carlin et al., 1992 , Carlin et al., 1997 . 24 (36) combination with those described in the previous publication (Lundahl et al., 2009) suggest that M1 is not a principal metabolite in humans. It was not detected when a more sensitive and selective analytical method was applied (LC-MS/MS) and when the therapeutic dose of finasteride was administered. The identification of MX and MY has broadened the knowledge of the metabolism of finasteride in male subjects. However, the finding of MX and MY indicates that there are at least one other parallel pathway of metabolism competing with the formation of M3 (Fig.1) .
In this study, both MX and MY were identified in human bile and this is the first time that metabolite identification for finasteride has been performed directly in human bile. Metabolite identification in rat bile has been performed and preliminary data have been reported (Ishii et al., 1992) . In male rats, biliary excretion of metabolites accounted for approximately 64% of the oral finasteride dose. In humans, almost 60% of a radioactive dose was recovered in feces as metabolites and this indicated that biliary excretion was probably the major route of elimination for these metabolites (Carlin et al., 1992) . However, the metabolites found in feces were not identified. Radioactively labeled drug detected in feces has been traditionally used to estimate the amount of drug excreted via bile in humans (Ghibellini et al., 2006a) . This mass balance approach, however, does not distinguish between amount of unabsorbed parent drug and amount unchanged drug excreted in bile. The approach is further limited by additional factors such as: i) biliary clearance is impossible to estimate with feces sampling, ii) feces collection results in a difficult matrix for metabolite identification and iii) unstable metabolites, for example glucuronides that are being hydrolyzed by enzymes along the intestine, can be difficult to quantify properly. By collecting bile directly from the small intestine (proximal jejunum)
This article has not been copyedited and formatted. The final version may differ from this version. 25 (36) it is possible to estimate biliary clearance (Bergman et al., 2006 , Ghibellini et al., 2006a and directly search for metabolites, including intact glucuronides in a relatively simple matrix. This can provide a more accurate prediction of the exposure of the drug and its metabolites to the liver, gall bladder and biliary duct. One previous example of metabolite identification directly in bile is the identification of a new glucuronide of piperacillin after sampling from healthy volunteers via an oroenteric tube (Ghibellini et al., 2006b) . Another example of a more advanced and complicated method for bile collection and metabolite identification is the application of a nasobiliary drainage tube to cholangiocarcinoma patients (Teichert et al., 2009 ). However, this advanced method can not be applied to healthy volunteers.
In this study, the sampling of bile from healthy volunteers was performed with an intestinal single-pass perfusion technique, Loc-I-Gut, which has been used for many years by this research team with the main purpose to study drug permeability, absorption and dissolution (Lennernäs et al., 1992 , Knutson et al., 1989 , Bonlokke et al., 1999 .
More recently, the method has been utilized to investigate the biliary excretion of drugs and metabolites after collection of the biliary fluid secreted to the upper part of the jejunum (Bergman et al., 2006 , Persson et al., 2006 . Bile was collected for 3 hours after finasteride administration and M1, M3 and finasteride were quantified with LC-MS/MS and reported in a pharmacokinetic herb-drug interaction study (Lundahl et al., 2009 The objective of this study was not only to search for phase I metabolites but also to identify phase II metabolites excreted to bile and/or urine. Phase II metabolism for finasteride has been briefly reported. In dog, there was indirect evidence (after hydrolysis) for glucuronide formation and in rat, one glucuronide was found in bile (Carlin et al., 1997 , Ishii et al., 1992 . In this study, MY glucuronide, was discovered in both bile and urine from all investigated subjects. Identification of this glucuronide in bile indicates that MY can probably undergo enterohepatic circulation, after hydrolysis and intestinal re-absorption, leading to possible increased hepatobiliary exposure and an expected long terminal plasma half-life. Today, there is no information on the safety aspects of this finding. Finasteride has a terminal half-life of ~5 hours in humans but its pharmacodynamic effect lasts up to 72 hours (Ohtawa et al., 1991) . Contribution of an active metabolite with a long half-life could explain this observation. However, an alternative explanation may be that finasteride binds irreversibly to 5α-reductase and that the biosynthesis of new enzyme takes up to 72 hours (Tian, 1996 , Faller et al., 1993 (Benet et al., 1993 , Shipkova et al., 2003 . The identification of M3 glucuronide may be an important finding and should thus be further investigated.
Finasteride has been on the market for almost two decades and is considered a safe drug in long-treatment effect studies (Lowe et al., 2003 , Vaughan et al., 2002 .
However, few published investigations examine the pharmacokinetics and metabolism of the drug. Recently, a clinical practice guideline was published with recommendations on the use of 5α-reductase inhibition in prostate cancer chemoprevention (Kramer et al., 2009) . If finasteride will come to be used for chemoprevention in healthy men and prescribed to a wider population, we believe that it is important to have a broader understanding of the metabolism of this drug. With this study new information about the metabolism of finasteride has been given and novel metabolites have been identified in human bile and urine. Further investigation is needed to understand the importance of this finding both from a safety and efficacy perspective.
In summary, M3, two hydroxy-metabolites, MX and MY, and one intact glucuronide, MY glucuronide, were identified in both human bile and urine. For the first time, intact glucuronides of finasteride was identified. MY glucuronide was the main glucuronide, found both in bile and urine and low amounts of M3 glucuronide, an acylglucuronide, were identified in human bile. To our knowledge, this is the first time that human bile has been used for the identification of previously unknown metabolites of finasteride.
This article has not been copyedited and formatted. The final version may differ from this version. M1-M4 have previously been described (Huskey et al., 1995) . 
